DORNA YAGHOOBZADEH: Open Payments
NPI 1760969943 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,155 in 232 payments from 18 companies in 2025. Trend: 2023 $3,545 · 2024 $4,127 · 2025 $4,155
Food & beverage: $4,070Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $994 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 72 | $921 |
| Janssen Biotech, Inc. | 22 | $416 |
| QOL Medical, LLC | 12 | $297 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $247 |
| Ardelyx, Inc. | 12 | $226 |
| PFIZER INC. | 12 | $222 |
| Regeneron Healthcare Solutions, Inc. | 10 | $213 |
| GENZYME CORPORATION | 4 | $113 |
| Aimmune Therapeutics, Inc. | 4 | $105 |
Products named: XIFAXAN, RINVOQ, TREMFYA, Sucraid, DUPIXENT, SKYRIZI, IBSRELA, ENTYVIO.
Industry payments across CA — which companies pay providers there.
